1. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
- Author
-
European Network for Individualized Treatment in Endometrial Cancer, Willem Jan van Weelden, Roy I. Lalisang, Johan Bulten, Kristina Lindemann, H.J. (Heleen) van Beekhuizen, Hans Trum, Dorry Boll, Henrica M.J. Werner, Luc R.C.W. Van Lonkhuijzen, Refika Yigit, David Forsse, Petronella O. Witteveen, Khadra Galaal, Alexandra van Ginkel, Eliana Bignotti, Vit Weinberger, Sanne Sweegers, Judith R. Kroep, Silvia Cabrera, Marc P.L.M. Snijders, Márcia A. Inda, Ane Gerda Z. Eriksson, Camilla Krakstad, Andrea Romano, Anja van de Stolpe, Johanna M.A. Pijnenborg, European Network for Individualized Treatment in Endometrial Cancer, Willem Jan van Weelden, Roy I. Lalisang, Johan Bulten, Kristina Lindemann, H.J. (Heleen) van Beekhuizen, Hans Trum, Dorry Boll, Henrica M.J. Werner, Luc R.C.W. Van Lonkhuijzen, Refika Yigit, David Forsse, Petronella O. Witteveen, Khadra Galaal, Alexandra van Ginkel, Eliana Bignotti, Vit Weinberger, Sanne Sweegers, Judith R. Kroep, Silvia Cabrera, Marc P.L.M. Snijders, Márcia A. Inda, Ane Gerda Z. Eriksson, Camilla Krakstad, Andrea Romano, Anja van de Stolpe, and Johanna M.A. Pijnenborg
- Abstract
Background: Approximately 20% of women with endometrial cancer have advanced-stage disease or suffer from a recurrence. For these women, prognosis is poor, and palliative treatment options include hormonal therapy and chemotherapy. Lack of predictive biomarkers and suboptimal use of existing markers for response to hormonal therapy have resulted in overall limited efficacy. Objective: This study aimed to improve the efficacy of hormonal therapy by relating immunohistochemical expression of estrogen and progesterone receptors and estrogen receptor pathway activity scores to response to hormonal therapy. Study Design: Patients with advanced or re
- Published
- 2021
- Full Text
- View/download PDF